Shu-Tung Li
Keine laufenden Positionen mehr
Profil
Shu-Tung Li is the founder of Collagen Matrix, Inc. (founded in 1997) and ReGen Biologics, Inc. (founded in 1987).
At Collagen Matrix, he held the titles of President & Chief Executive Officer from 2011 to 2015.
At ReGen Biologics, he held the title of Director, EVP-Research & Development from 1987 to 2011.
Dr. Li's former jobs include Director-Implants Development at Meadox Medicals, Inc., Vice President-Research & Development at Integra LifeSciences Holdings Corp., Vice President-Research & Development at CollaTech, Inc., and Assistant Professor at the University of Connecticut Health Center.
Dr. Li earned a doctorate degree from the University of Connecticut.
Ehemalige bekannte Positionen von Shu-Tung Li
Unternehmen | Position | Ende |
---|---|---|
Collagen Matrix, Inc.
Collagen Matrix, Inc. Medical SpecialtiesHealth Technology Collagen Matrix, Inc. design and manufactures extracellular matrices for tissue and organ repair and regeneration. The firm offers collagen and mineral-based finished medical devices in the areas of orthopedic-spine surgery, neurosurgery, oral surgery, and wound care. It provides DuraMatrix, Neuroflex, NeuroMatrix, OssiMend, and the Matrix Collagen. The company was founded by Shu-Tung Li in 1997 and is headquartered in Oakland, NJ. | Vorstandsvorsitzender | 23.09.2015 |
University of Connecticut Health Center
University of Connecticut Health Center Other Consumer ServicesConsumer Services University of Connecticut Health Center provides healthcare services. It is an organization, which composed of the school of medicine, John Dempsey hospital, the UConn medical group & health partners, and university dentists. It offers services for cardiovascular, cancer, behavioral, ambulatory, and neonatal intensive-care. The company was founded in 1961 and is headquartered in Farmington, CT. | Corporate Officer/Principal | - |
Meadox Medicals, Inc.
Meadox Medicals, Inc. Medical SpecialtiesHealth Technology Part of Boston Scientific Corp., Meadox Medicals, Inc. makes vascular replacement devices. The company is based in Oakland, NJ. Meadox Medicals was acquired by Boston Scientific Corp. on November 20, 1995 for $425 million. | Corporate Officer/Principal | - |
INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | - |
CollaTech, Inc.
CollaTech, Inc. Packaged SoftwareTechnology Services CollaTech, Inc. produces electronic commerce software. The private company is based in Champaign, IL and has subsidiaries in the United States. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Shu-Tung Li
University of Connecticut | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
REGEN BIOLOGICS INC. | Health Services |
INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Health Technology |
Private Unternehmen | 3 |
---|---|
Collagen Matrix, Inc.
Collagen Matrix, Inc. Medical SpecialtiesHealth Technology Collagen Matrix, Inc. design and manufactures extracellular matrices for tissue and organ repair and regeneration. The firm offers collagen and mineral-based finished medical devices in the areas of orthopedic-spine surgery, neurosurgery, oral surgery, and wound care. It provides DuraMatrix, Neuroflex, NeuroMatrix, OssiMend, and the Matrix Collagen. The company was founded by Shu-Tung Li in 1997 and is headquartered in Oakland, NJ. | Health Technology |
CollaTech, Inc.
CollaTech, Inc. Packaged SoftwareTechnology Services CollaTech, Inc. produces electronic commerce software. The private company is based in Champaign, IL and has subsidiaries in the United States. | Technology Services |
Meadox Medicals, Inc.
Meadox Medicals, Inc. Medical SpecialtiesHealth Technology Part of Boston Scientific Corp., Meadox Medicals, Inc. makes vascular replacement devices. The company is based in Oakland, NJ. Meadox Medicals was acquired by Boston Scientific Corp. on November 20, 1995 for $425 million. | Health Technology |